Kahn Swick & Foti and partner Charles C. Foti, Jr. say investors who acquired Ardent Health securities between July 18, 2024 and November 12, 2025 have until March 9, 2026 to file lead plaintiff applications in the securities class action.

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ardent Health, Inc. ("Ardent" or the "Company") (NYSE: ARDT), if they purchased or otherwise acquired the Company's securities between July 18, 2024 and November 12, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Middle District of Tennessee.

What You May Do

If you purchased securities of Ardent and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-ardt/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 9, 2026.

About the Lawsuit

Ardent and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 12, 2025, post-market, the Company disclosed a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after the Company transitioned to a new revenue accounting system and from purported "recently completed hindsight evaluations of historical collection trends." The Company further disclosed a cut to 2025 EBITDA guidance of $57.5 million at the midpoint, or about 9.6%, from $575 million – $625 million to $530 million – $555 million due to "persistent industry-wide cost pressures," including "payer denials," and also recorded a $54 million increase in professional liability reserves "with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and 2022 in New Mexico" as well as "consideration of broader industry trends, including social inflationary pressures."

On this news, the price of Ardent's shares fell $4.75 per share, or nearly 34%, from $14.05 per share on November 12, 2025, to close at $9.30 per share on November 13, 2025, on unusually heavy trading volume.

The case is Postiwala v. Ardent Health, Inc., et al., No. 26-cv-00022.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478971667/2227/2026-05-12T01:21:03